Price: $15.17
· 1 day: +1.81% · 5 days: -0.78% · 1 month: +16.07% · YTD: -34.04%
As of 2026-10-15 20:00 UTC.
52-week range: $12.73 – $39.89 (currently at 9% of the range).
The brief
RARE is in a downtrend, momentum firm. $16 is the level overhead; $15 the first support below.
4 of 6 technical checks lean bearish.
Price vs 50-day: below
Price vs 200-day: below
50d vs 200d avg: below
MACD: bullish
RSI momentum: 57
5-day tape: -0.8%
Trend
Downtrend · below 50-day & below 200-day
Momentum
RSI 57.17 · bearish · MACD bullish
Trend strength
ADX 18.6 · weak or range
Location
-21.2% vs 50-day MA
52-week range
-58% from high · +18% from low
Volatility
ATR 0.72 · ~4.7%/day
Key levels
Level
Type
Distance
$16.0 (resistance)
round
5.47%
$17.0 (resistance)
round
12.06%
$19.26 (resistance)
sma 50
26.96%
$15.0 (support)
round
-1.12%
$14.09 (support)
swing zone
-7.12%
$14.0 (support)
round
-7.71%
Indicators
RSI (14)
57.17
MACD
-0.9417
ADX (14)
18.6
ATR (14)
0.72
50-day average
$19.26
200-day average
$23.3
Next earnings: 2026-11-03.
Latest RARE news
Ultragenyx Pharmaceutical Inc. — Form 8-K: 1.01 Entry into a Material Agreement — ```json
{
"summary": "Ultragenyx Pharmaceutical Inc. filed a Form 8-K on October 14, 2026, disclosing entry into a material agreement. The filing indicates a significant contractual commitment requiring SEC disclosure (SEC EDGAR, 2026-10-14)
Ultragenyx Pharmaceutical Inc. — Form 8-K: 1.01 Entry into a Material Agreement — ```json
{
"summary": "Ultragenyx Pharmaceutical Inc. filed a Form 8-K on October 7, 2026, disclosing entry into a material agreement. The specific terms, counterparty, and financial details of the agreement are not pro (SEC EDGAR, 2026-10-07)
Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology — Minaris and Asimov announced a partnership to integrate Minaris' OXGENE technology into Asimov's AAV Edge producer cell lines, aiming to improve manufacturing titers and product quality for AAV gene therapies. The collab (PR Newswire, 2026-09-24)